ANAPTYSBIO Files 8-K on Financial Results & Reg FD Disclosure

Ticker: ANAB · Form: 8-K · Filed: Jan 5, 2024 · CIK: 1370053

Anaptysbio, Inc 8-K Filing Summary
FieldDetail
CompanyAnaptysbio, Inc (ANAB)
Form Type8-K
Filed DateJan 5, 2024
Risk Levelmedium
Pages3
Reading Time3 min
Key Dollar Amounts$0.001, $417 million
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: financial-condition, regulation-fd, corporate-update

TL;DR

**ANAPTYSBIO just dropped an 8-K, likely with fresh financials or big news; check the details ASAP!**

AI Summary

ANAPTYSBIO, INC. filed an 8-K on January 5, 2024, reporting under Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure). This filing indicates that the company likely released financial results or other material non-public information on this date. For investors, this matters because it signals a recent disclosure of key financial performance or strategic updates that could influence the stock's valuation and future prospects, requiring a deeper dive into the specific content of the disclosed information.

Why It Matters

This filing indicates ANAPTYSBIO, INC. has likely released new financial information or other significant updates, which could impact investor perception and stock price. Investors should seek out the specific content of the disclosure to understand its implications.

Risk Assessment

Risk Level: medium — The filing itself is administrative, but the underlying event (likely financial disclosure) could carry significant risk or opportunity depending on the content.

Analyst Insight

A smart investor would immediately seek out the full content of the disclosures referenced under Item 2.02 and Item 7.01 to understand the specific financial results or material information released by ANAPTYSBIO, INC. on January 5, 2024, before making any investment decisions.

Key Numbers

  • 001-37985 — Commission File Number (unique identifier for ANAPTYSBIO, INC. with the SEC)
  • 20-3828755 — IRS Employer Identification No. (tax identification number for ANAPTYSBIO, INC.)
  • January 5, 2024 — Date of Report (date the earliest event reported in the 8-K occurred)

Key Players & Entities

  • ANAPTYSBIO, INC. (company) — the registrant filing the 8-K
  • Delaware (company) — state of incorporation for ANAPTYSBIO, INC.
  • The Nasdaq Stock Market LLC (company) — exchange where ANAPTYSBIO, INC.'s Common Stock is registered
  • ANAB (company) — trading symbol for ANAPTYSBIO, INC.

Forward-Looking Statements

  • ANAPTYSBIO, INC. will release detailed financial results for a recent period. (ANAPTYSBIO, INC.) — high confidence, target: Q1 2024
  • The stock price of ANAB will react to the specific content of the financial disclosure. (ANAB) — medium confidence, target: January 2024

FAQ

What specific items were reported in this 8-K filing by ANAPTYSBIO, INC.?

ANAPTYSBIO, INC. reported under Item 2.02, 'Results of Operations and Financial Condition,' and Item 7.01, 'Regulation FD Disclosure,' as indicated in the filing on January 5, 2024.

What is the trading symbol and the exchange where ANAPTYSBIO, INC.'s common stock is registered?

The trading symbol for ANAPTYSBIO, INC.'s common stock is ANAB, and it is registered on The Nasdaq Stock Market LLC, according to the filing.

What is the business address of ANAPTYSBIO, INC. as stated in the filing?

The business address of ANAPTYSBIO, INC. is 10770 Wateridge Circle, Suite 210, San Diego, CA 92121, with a telephone number of (858) 362-6295, as per the 8-K.

When was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 5, 2024, which is also the Date of Report.

What is ANAPTYSBIO, INC.'s state of incorporation and Commission File Number?

ANAPTYSBIO, INC. is incorporated in Delaware, and its Commission File Number is 001-37985, as stated in the 8-K filing.

Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 11.7 · Accepted 2024-01-05 16:09:38

Key Financial Figures

  • $0.001 — ch registered Common Stock, par value $0.001 per share ANAB The Nasdaq Stock Marke
  • $417 million — alents and investments of approximately $417 million as of December 31, 2023. Anaptys' audi

Filing Documents

02. Results of Operations and Financial Condition

Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, AnaptysBio, Inc. ("Anaptys") expects to present certain preliminary, unaudited financial information in connection with presentations (the "Presentation") at the J.P. Morgan Healthcare Conference, including that Anaptys expects to report that it had cash and cash equivalents and investments of approximately $417 million as of December 31, 2023. Anaptys' audited financial statements for the fiscal year ended December 31, 2023 are not yet available. Accordingly, the preliminary financial information included in the Presentation is an estimate subject to the completion of Anaptys' financial closing procedures and any adjustments that may result from the completion of the audit of Anaptys' financial statements. The preliminary financial information may differ materially from the actual results that will be reflected in Anaptys' audited financial statements when they are completed and publicly disclosed. Additional information and disclosures would be required for a more complete understanding of Anaptys' financial position and results of operations as of December 31, 2023. The information in this Item 2.02 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended. The information contained in this Item 2.02 shall not be incorporated by reference into any registration statement or other document filed by Anaptys with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form 8-K generally), except as shall be expressly set forth by specific reference in such filing.

01. Regulation FD

Item 7.01. Regulation FD. Anaptys is furnishing the Presentation, a full copy is attached hereto as Exhibit 99.1. The information in this Item 7.01, including Exhibit 99.1, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Title or Description 99.1 Anaptys Corporate Presentation January 2024. 104 Cover Page Interactive Data File (the cover page XBRL tags are embedded within the inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. AnaptysBio, Inc. Date: January 5, 2024 By: /s/ Dennis Mulroy Name: Dennis Mulroy Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.